Non-Current Assets
Equity Method Investments
Eli Lilly Equity Method Investments decreased by 0.2% to $2.80B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 12.9%, from $3.22B to $2.80B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a -1.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
Detailed definition
These are investments in entities where the company exercises significant influence but does not have full control. The...
Peer comparison
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
Metric ID:
equity_method_investmentsHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.47B | $3.35B | $3.21B | $2.73B | $2.59B | $2.57B | $2.90B | $2.75B | $2.75B | $2.69B | $3.05B | $3.09B | $2.88B | $3.20B | $3.22B | $3.22B | $3.21B | $2.81B | $2.80B |
| QoQ Change | — | -3.6% | -4.1% | -15.1% | -5.1% | -0.5% | +12.7% | -5.2% | -0.2% | -1.9% | +13.4% | +1.1% | -6.8% | +11.2% | +0.5% | +0.2% | -0.5% | -12.4% | -0.2% |
| YoY Change | — | — | — | — | -25.5% | -23.2% | -9.7% | +0.8% | +6.1% | +4.5% | +5.2% | +12.2% | +4.8% | +18.9% | +5.4% | +4.4% | +11.5% | -12.2% | -12.9% |
Range$2.57B – $3.47B
CAGR-4.7%
Avg YoY Growth-0.6%
Median YoY Growth+4.5%
Current Streak3 quarters decline
Equity Method Investments at Other Companies
Frequently Asked Questions
- What is Eli Lilly's equity method investments?
- Eli Lilly (LLY) reported equity method investments of $2.80B in Q4 2025.
- How has Eli Lilly's equity method investments changed year-over-year?
- Eli Lilly's equity method investments decreased by 12.9% year-over-year, from $3.22B to $2.80B.
- What is the long-term trend for Eli Lilly's equity method investments?
- Over 5 years (2020 to 2025), Eli Lilly's equity method investments has grown at a -1.1% compound annual growth rate (CAGR), from $2.97B to $2.80B.
- What does equity method investments mean?
- The value of investments in other companies where the firm has significant influence but not total control.